On April 22, 2026, DOJ and DEA took two coordinated steps that could reshape—though not resolve—the federal treatment of marijuana. First, they issued a final order placing certain FDA-approved and state-licensed medical marijuana products in Schedule III of the Controlled Substances Act. At the same time, DEA announced an expedited hearing on a separate proposal to reclassify marijuana more broadly from Schedule I to Schedule III, with proceedings set to begin in late June. Together, these actions signal movement toward a less restrictive federal framework, but their immediate impact is narrower than it may appear: the final order applies only to a limited subset of medical marijuana products and leaves most cannabis activity subject to existing federal controls. For industry participants, the developments introduce a more compliance-driven, state license-dependent pathway today, while setting the stage for potentially more significant changes in the months ahead.

(more…)